Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Update Il y a 4 ans
Reference: NCT00776503

Woman and Man

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of this study is to determine the maximum tolerated duration and schedule of oral VORINOSTAT in addition to low dose cytarabine in the treatment of Intermediate-2 and High risk myelodysplastic syndromes.


Inclusion criteria

  • Myelodysplastic syndromes

Links